Apollomics, Inc. (NASDAQ:APLM) Short Interest Up 32.7% in October

Apollomics, Inc. (NASDAQ:APLM) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 333,700 shares, an increase of 32.7% from the September 30th total of 251,400 shares. Based on an average trading volume of 3,570,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.5% of the company’s stock are sold short.

Apollomics Stock Up 2.2 %

APLM stock opened at $0.14 on Monday. The stock’s 50 day simple moving average is $0.13 and its 200 day simple moving average is $0.23. Apollomics has a 12-month low of $0.11 and a 12-month high of $1.79.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Apollomics stock. Exchange Traded Concepts LLC boosted its holdings in Apollomics, Inc. (NASDAQ:APLM) by 247.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,259,117 shares of the company’s stock after buying an additional 896,316 shares during the quarter. Exchange Traded Concepts LLC owned 1.41% of Apollomics worth $179,000 at the end of the most recent quarter. 19.13% of the stock is currently owned by institutional investors and hedge funds.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.